Mumbai, February 17, 2026 – Indian equities faced renewed pressure in the latest trading session, with Nifty dipping amid FII outflows and Q3 earnings disappointment from consumer and mid-cap sectors. Over 30 scrips hit fresh 52-week lows, led by sharp drops in AGARIND (down 11.45% to ₹640.65 on agro slowdown), NEPHROCARE (sliding 9.6% to ₹80 amid diagnostics woes), and CLEDUCATE (falling 5.26% to ₹45.75 on education sector pressures). This extends February's volatility, with SMEs and mid-caps bearing the brunt on leverage unwind and weak demand signals.
The slide reflects broader caution ahead of budget and global cues, with volumes down 12% and decliners leading 1.5:1. Analysts see oversold bounces possible if PMI data surprises positively, but downside risks linger if FII selling persists.
Top 52-Week Low Decliners (Sorted by % Decline)
Here's a snapshot of the sharpest plungers in the latest session, from BSE/NSE data:
| Rank | Symbol | Series | LTP (₹) | % Change | New 52W Low (₹) | Prev. Low (₹) | Prev. Low Date |
|---|---|---|---|---|---|---|---|
| 1 | AGARIND | EQ | 640.65 | -11.45 | 591.65 | 593.70 | 16-Feb-2026 |
| 2 | NEPHROCARE | SM | 80.00 | -9.60 | 76.00 | 87.00 | 16-Feb-2026 |
| 3 | CLEDUCATE | EQ | 45.75 | -5.26 | 44.01 | 48.00 | 16-Feb-2026 |
| 4 | AISL | SM | 68.50 | -2.84 | 67.50 | 69.10 | 13-Feb-2026 |
| 5 | AURIGROW | BE | 0.33 | -2.94 | 0.33 | 0.34 | 13-Feb-2026 |
| 6 | BALAXI | EQ | 22.00 | -0.18 | 21.82 | 21.90 | 11-Feb-2026 |
| 7 | BETA | EQ | 1,133.00 | 0.27 | 1,098.90 | 1,105.00 | 16-Feb-2026 |
| 8 | BIOPOL | ST | 102.00 | 1.75 | 95.25 | 100.25 | 16-Feb-2026 |
| 9 | BLUECOAST | EQ | 23.17 | -4.73 | 23.12 | 23.53 | 16-May-2025 |
| 10 | BLUEJET | EQ | 362.85 | 1.47 | 352.55 | 357.60 | 16-Feb-2026 |
| 11 | BLUESTONE | EQ | 404.35 | -1.50 | 403.40 | 404.00 | 16-Feb-2026 |
| 12 | CELLO | EQ | 467.60 | -2.02 | 466.55 | 468.00 | 16-Feb-2026 |
| 13 | CLEAN | EQ | 751.85 | 1.02 | 737.55 | 740.10 | 16-Feb-2026 |
Key Spotlights:
- AGARIND's Agro Slump: Tanked 11.45% to ₹640.65, brushing new low on input cost hikes—volumes spiked.
- NEPHROCARE's Diagnostics Dip: Down 9.6% to ₹80, hit by demand slowdown; SME pain point.
- CLEDUCATE's Education Pressure: Slid 5.26% to ₹45.75 amid sector weakness.
- Broader Weakness: AISL (-2.84% to ₹68.50) and AURIGROW (-2.94% to ₹0.33) extended losses on capex caution.
